共 50 条
- [21] Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than DeathJAMA INTERNAL MEDICINE, 2021, 181 (09) : 1217 - 1223Lalani, ChristinaKunwar, Elysha M.Kinard, MadrisDhruva, Sanket S.Redberg, Rita F.
- [22] 10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 InhibitorsJOURNAL OF SEXUAL MEDICINE, 2012, 9 (01): : 265 - 270Lowe, GregoryCostabile, Raymond A.
- [23] Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting SystemJournal of Pharmaceutical Health Care and Sciences, 5Graça M. DoresSilvia Perez-VilarManette T. Niu
- [24] Assessment of patient-initiated adverse event reports received by the Food and Drug Administration from patients like mePHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 257 - 257Brajovic, SonjaOkun, SallySahoo, SanjayHall, MarniPamer, Carol
- [25] Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting SystemJOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2019, 5 (01)Dores, Graca M.Perez-Vilar, SilviaNiu, Manette T.
- [26] Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor UseJOURNAL OF NEURO-OPHTHALMOLOGY, 2016, 36 (04) : 480 - 481Li, Albert S.Pomeranz, Howard D.
- [27] Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administrationPHARMACOTHERAPY, 2004, 24 (06): : 743 - 749Hartnell, NRWilson, JP
- [28] Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug AdministrationPHARMACOTHERAPY, 2019, 39 (11): : 1042 - 1052Munoz, Monica A.Delcher, ChrisDal Pan, Gerald J.Kortepeter, Cindy M.Wu, EileenWei, Yu-Jung JennyXiao, HongWinterstein, Almut G.
- [29] Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)CLINICAL DRUG INVESTIGATION, 2017, 37 (12) : 1143 - 1152Rahman, Md. MotiurAlatawi, YasserCheng, NingQian, JingjingPeissig, Peggy L.Berg, Richard L.Page, David C.Hansen, Richard A.
- [30] Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS)Clinical Drug Investigation, 2017, 37 : 1143 - 1152Md. Motiur RahmanYasser AlatawiNing ChengJingjing QianPeggy L. PeissigRichard L. BergDavid C. PageRichard A. Hansen